RxDoctor Payments Data

Jeffrey Crowder, MD

Ophthalmology · Gainesville, GANPI 1528063781

Payments from drug & device makers

$12,704in general payments, 2019–2025

Across 186 payments — averaging $68.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Biotissue Holdings Inc.$2K
  • Glaukos Corporation$1K
  • Lensar, Inc.$631
  • Sun Pharmaceutical Industries Inc.$526
  • AbbVie$504
  • plus $5K from 23 others

What the payments were for

  • Consulting fees$4003%
  • Travel & lodging$1,77714%
  • Food & beverage$10,28681%
  • Education$2412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,704 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$323,470
Medicare patients
876
Services billed
2,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine35$51,787
XiidraLifitegrast18$28,447
Cyclosporine24$25,885
RhopressaNetarsudil Mesylate28$10,393
Latanoprost600$8,810
RocklatanNetarsudil Mesylat/Latanoprost13$7,645
LumiganBimatoprost12$6,691
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat286$5,423
Prednisolone Acetate115$5,106
Travoprost16$3,494
Ketorolac Tromethamine129$2,590
Timolol Maleate216$2,361
Loteprednol Etabonate13$1,845
Brimonidine Tartrate111$1,022
Dorzolamide Hcl26$555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$504$58,47847 claims
Bausch & Lomb Americas Inc.Xiidra$261$28,44718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →